Telix Pharmaceuticals establishes Japanese subsidiary

This article was originally published here

Published 16 January 2018

Australian biopharmaceutical firm Telix Pharmaceuticals has established Telix Pharmaceuticals (Japan) (Telix Japan) and appointed first two members of the Japanese leadership team.

Telix Japan is wholly-owned operating subsidiary of Telix Pharmaceuticals Limited. The purpose of the subsidiary is to support the Company’s Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in the Japan, an important market for Telix’s products.

To lead the Telix Japan activities, Dr. Shintaro Nishimura and Dr. Takeshi Oka have been appointed as President and Chief Operating Officer, and Chief Medical Officer (Japan), respectively.

Telix Co-Founder and CEO Dr. Christian Behrenbruch said: “Japan is one of the most important prospective markets for Telix’s products and our activities in Japan covers a range of manufacturing and collaboration activities with leading Japanese clinical sites and biopharmaceutical companies.

The Japanese radiopharmaceutical landscape is evolving rapidly, and we are pleased to have been able to hire two extremely high-caliber executives to lead our development and commercial activity.”

Dr. Nishimura stated, “Telix has an exciting commercial opportunity for its products in Japan and Dr. Oka and I are pleased to be leading the Company’s activities in the Japanese market. There is considerable interest in Telix’s oncology pipeline from our top nuclear medicine clinics and we hope to use this interest to obtain the additional data required to meet the marketing authorization requirements of the Pharmaceuticals and Medical Devices Agency (PMDA)1 to make Telix’s technology available to Japanese cancer patients.”

Telix is an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR).

The Company is developing an advanced portfolio of oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.

Source: Company Press Release

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply